|

CTNNA1 Familial Expansion Study

RECRUITINGSponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
SponsorAbramson Cancer Center at Penn Medicine
Started2021-03-16
Est. completion2028-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* 18 years of age and older
* Participants must be carrier, or a first degree relative of a carrier, of a CTNNA1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a consensus splice site variant predicted to disrupt splicing in CTNNA1. CTNNA1 loss-of-function variants do not need to be classified as pathogenic or likely pathogenic to be included.
* Participants must be able to understand and read English
* Participants must be able to provide informed verbal or written consent

Exclusion Criteria:

* Less than 18 years of age
* Individuals who do not carry a CTNNA1 loss-of-function variant and are not a first degree relative of a CTNNA1 loss-of-function variant carrier.
* Individuals who cannot speak and read English
* Major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation
* Unable to comply with the study procedures as determined by the study investigators or study staff

Conditions4

Breast CancerCancerCancer Gene MutationGastric Cancer

Locations1 site

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Bryson Katona, MD, PhD215-349-8222cafestudy@pennmedicine.upenn.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.